A Breakthrough in Stroke Rehabilitation: Non-Invasive Biophoton Therapy Promotes Neurofunctional Recovery in Chronic Stroke Patients

What does your doctor think? Better than these?

60 Hertz flickering light (5 posts to July 2021)

40 Hertz flickering light (7 posts to March 2021)

Biophoton therapy is a form of complementary and alternative light therapy that uses specific wavelengths of light to stimulate the body's natural self-healing processes

. It is based on the theory that living cells emit very low levels of light, or "biophotons," which play a role in cellular communication and regulation.

Yes, biophotons are real; they are extremely faint light particles (ultra-weak photon emissions or UPE) emitted by all living cells as byproducts of metabolic processes, detectable with sensitive equipment but invisible to the naked eye, and research suggests they play roles in cellular communication, signaling, and potentially even health indicators.  

 A Breakthrough in Stroke Rehabilitation: Non-Invasive Biophoton Therapy Promotes Neurofunctional Recovery in Chronic Stroke Patients

James Z Liu1,2*, Helen Y Gu1,2, Mariola Smotrys1, Seth Robinson2, Huixia Yu2, Devin R Liu2, and Sherry Liu1 1First Institute of All Medicines, 139 Pittsburgh Road, Butler, PA 16001, USA 2Tesla Bio Healing, LLC. 111 McCoy Street, Milford, DE 19963, USA 

 ABSTRACT 

Background: 

Effective treatments for chronic stroke remain a critical unmet medical need. Conventional rehabilitation approaches often yield limited functional recovery, especially in patients with long-standing deficits. Emerging evidence suggests that biophoton-based therapies may offer a novel, non invasive solution to support neuroregeneration. 

Objective: 

To evaluate the therapeutic efficacy and safety of Automatic Biophoton Generators (ABGs) in patients with chronic stroke using validated clinical, neurological, and neurophysiological outcome measures. 

Methods: 

A randomized, triple-blind, placebo-controlled clinical trial was conducted with 46 chronic stroke patients who received either active ABG treatment (n = 26) or placebo devices (n = 20) over two weeks. Participants in the placebo group were later crossed over to receive active treatment for an additional four weeks. Each treatment group received therapy with 4 ABGs placed around a hotel bed. Stroke recovery was assessed using the Stroke Impact Scale (SIS), SF-36 quality-of-life survey, clinician-led neurological examinations, and quantitative Electroencephalography (qEEG) with Event Related Potentials (ERP). Additional evaluations included 3D Non-Linear Scanning (3D-NLS) for energetic brain imaging and Bio-Well analysis for organ and meridian energy coherence. 

Results: 

Biophoton therapy resulted in statistically significant improvements in SIS scores, stroke recovery rate, neurological exam scores, and quality-of life measures (p < 0.01). qEEG revealed increased posterior alpha frequencies, reduced theta/beta ratios, and improved ERP latencies, indicating enhanced attention, memory processing, and cognitive speed. 3D-NLS imaging showed rapid cortical reactivation and restored hemispheric balance after only 6 days of therapy. Bio-Well analysis demonstrated systemic energy restoration across the brain, cardiovascular system, and endocrine organs. No adverse events were reported. 

Conclusion: 

This study provides strong clinical and neurophysiological evidence that ABG-based biophoton therapy significantly improves functional outcomes in patients with chronic stroke. The therapy was well tolerated and offers a promising, non-invasive approach to address long-standing neurological impairments. These findings support the broader potential of biophoton quantum therapy in treating neurodegenerative and chronic inflammatory disorders.